• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Kite wins FDA approval for first adult CAR-T cell therapy

October 19, 2017 By Sarah Faulkner

Gilead SciencesMore than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults.

The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two other treatments.

The decision comes just two months after Gilead Sciences (NSDQ:GILD) paid $12 billion to acquire Kite. The company said yesterday that its CAR-T therapy, called Yescarta, will cost $373,000.

The Yescarta therapy is the second of its kind ever approved – the first was Novartis (NYSE:NVS), which won approval recently for its Kymriah therapy designed to treat acute lymphoblastic leukemia.

According to Yescarta’s official label, 72% of the 101 patients experienced a positive response after a one-time dose of cells and more than half had a complete response after nine months, according to Xconomy.

The nine-month data were better than the data collected from the same patients at three and six months. In other words, the cells seem to improve over time.

“This is going to change how we treat blood cancers and how we treat cancers in general,” Armin Ghobadi, an assistant professor of medicine at Washington University, told Xconomy.

Filed Under: Featured, Food & Drug Administration (FDA), Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, kitepharma, Novartis

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS